Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
September 21, 2023 08:00 ET
|
Replay Bio
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer Collaboration leverages JURA Bio’s T cell receptor (TCR) discovery platform...
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma
July 24, 2023 07:00 ET
|
Replay Bio
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma Phase 1 study of NY-ESO-1 TCR/IL-15 NK...
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma
June 20, 2023 07:00 ET
|
Replay Bio
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma First-in-human Phase 1 study of NY-ESO-1...
Cristian Massacesi, M.D., Appointed to Replay Board of Directors
May 25, 2023 07:00 ET
|
Replay Bio
Cristian Massacesi, M.D., Appointed to Replay Board of Directors Cristian Massacesi, M.D., Chief Medical Officer of AstraZeneca and Alexion and Oncology Chief Development Officer of AstraZeneca, to...
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
May 18, 2023 08:00 ET
|
Replay Bio
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company’s genomic medicine and engineered...
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy
February 14, 2023 07:01 ET
|
Replay Bio
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy Cord blood-derived T-Cell Receptor Natural Killer (TCR-NK) platform offers potential...
Replay targets genetic brain disorders with new gene therapy company, Kaleibe, utilising big DNA HSV technology
December 14, 2022 07:00 ET
|
Replay Bio
Replay targets genetic brain disorders with new gene therapy company, Kaleibe, utilising big DNA HSV technology Third product company from Replay expands use of next-generation high payload...
Replay receives $1.5 million grant for its hypoimmunogenic technology platform
November 28, 2022 07:00 ET
|
Replay Bio
Replay receives $1.5 million grant for its hypoimmunogenic technology platform Replay developing uCell™, its universal, off-the-shelf, genomically rewritten, renewable cell source hypoimmunogenic...
Replay launches big DNA HSV gene therapy company, Telaria, focused on rare skin diseases
November 21, 2022 07:00 ET
|
Replay Bio
Replay launches big DNA HSV gene therapy company, Telaria, focused on rare skin diseases Second product company using Replay’s next-generation high payload capacity HSV delivery vector developed at...
Replay launches its first HSV gene therapy company, Eudora, focused on retinal eye disease
October 31, 2022 07:00 ET
|
Replay Bio
Replay launches its first HSV gene therapy company, Eudora, focused on retinal eye disease First product company using Replay’s high payload capacity HSV vectorUtilizes a next-generation HSV...